<DOC>
	<DOCNO>NCT02820311</DOCNO>
	<brief_summary>The purpose study evaluate TD-4208 , investigational drug develop treat people chronic obstructive pulmonary disease ( COPD ) , effect electrical activity heart .</brief_summary>
	<brief_title>Thorough QT ( TQT ) Study TD-4208 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Subject body mass index ( BMI ) 19 32 kg/m2 , inclusive , weight least 55 kg . Subject able communicate well investigator comply study procedure , requirement , restriction . Subject prior history myocardial infarction , acute coronary syndrome , cerebrovascular accident , transient ischemic attack , ventricular tachycardia , atrial fibrillation , personal know family history congenital long QT syndrome know family history sudden death unknown cause , pacemaker implantable cardioverter defibrillator , cardiac cerebral stent placement angioplasty , clinically significant valvular heart disease . Subject evidence history clinically significant allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematologic , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Thorough QT ( TQT )</keyword>
	<keyword>cardiac safety</keyword>
</DOC>